Urinary tract infection. Urinary tract infection, site not specified
Conditions
Interventions
Intervention 1: Intervention group:In addition to receiving standard antibiotic treatment, patients will receive 5 mg melatonin tablets produced by Jalinous Iranian Pharmaceutical Company at a dose of
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
4 Years to 18 Years
Inclusion criteria
Inclusion criteria: Children aged 4-18 with urinary tract infection and sleep disorder at the same time Consent to participate in the study
Exclusion criteria
Exclusion criteria: The presence of underlying kidney disease
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: Within 10 days of starting antibiotic treatment and taking melatonin daily. Method of measurement: Thermometer.;Dysuria. Timepoint: Within 10 days of starting antibiotic treatment and taking melatonin daily. Method of measurement: Patient statements.;Urinary frequency. Timepoint: Within 10 days of starting antibiotic treatment and taking melatonin daily. Method of measurement: Patient statements.;Abdominal pain. Timepoint: Within 10 days of starting antibiotic treatment and taking melatonin daily. Method of measurement: Patient statements.;Urinary incontinence. Timepoint: Within 10 days of starting antibiotic treatment and taking melatonin daily. Method of measurement: Patient statements.;The number of Urinary frequency. Timepoint: Within 10 days of starting antibiotic treatment and taking melatonin daily. Method of measurement: Patient statements.;The number of Urinary incontinence. Timepoint: Within 10 days of starting antibiotic treatment and taking melatonin daily. Method of measurement: Patient statements. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirvali Azodzadeh Ardakani
Arak University of Medical Sciences
Outcome results
None listed